Amarin | AMRN - Stammkapital

Aktienkurs
14.48
Täglich Wechseln
-0.30 -2.03%
Monatlich
-11.27%
Jährlich
55.70%
Q2 Prognose
14.06




Stammkapital Veränderung Datum
AbbVie USD 1.77B 1.75B 2025-06
Alnylam Pharmaceuticals USD 132.38M 585K 2025-12
Amarin USD 20.81M 13K 2025-12
AstraZeneca USD 1.55B 206K 2025-12
BioCryst Pharmaceuticals USD 213.06M 2.54M 2025-12
DBV Technologies USD 136.82M 51.98K 2025-09
Esperion Therapeutics USD 245.22M 39.79M 2025-12
GlaxoSmithKline GBP 4.08B 49.43M 2025-12
Halozyme Therapeutics USD 117.78M 259K 2025-12
Heron Therapeutics USD 188.31M 4.99M 2025-12
Ionis Pharmaceuticals USD 161.97M 836K 2025-12
Nektar Therapeutics USD 20.38M 20.36M 2025-12
Neurocrine Biosciences USD 100.1M 400K 2025-12
Novartis USD 1.91B 10.64M 2025-12